The quest to unlock new treatments for obesity and cardiometabolic disease just got a significant boost, as Moonwalk Biosciences announced it has raised $70.0M in Series B funding.
The biotech firm is pioneering novel therapeutics in adipose biology and tissue, leveraging a discovery platform driven by deep genetic and epigenetic evidence and insights. This platform allows Moonwalk Biosciences to identify novel targets involved in these widespread conditions, and the company is currently advancing an early-stage pipeline of therapeutic candidates.
















